• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Dual gut hormone receptor agonists for diabetes and obesity.

作者信息

Bass Joseph, Tschöp Matthias H, Beutler Lisa R

机构信息

Northwestern University Feinberg School of Medicine, Department of Medicine, Division of Endocrinology, Metabolism and Molecular Medicine, Chicago, Illinois, USA.

Helmholtz Munich, Neuherberg, Germany.

出版信息

J Clin Invest. 2023 Feb 1;133(3):e167952. doi: 10.1172/JCI167952.

DOI:10.1172/JCI167952
PMID:36719381
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9888372/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/da75/9888372/9fccb961f181/jci-133-167952-g177.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/da75/9888372/9fccb961f181/jci-133-167952-g177.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/da75/9888372/9fccb961f181/jci-133-167952-g177.jpg

相似文献

1
Dual gut hormone receptor agonists for diabetes and obesity.用于治疗糖尿病和肥胖症的双肠道激素受体激动剂。
J Clin Invest. 2023 Feb 1;133(3):e167952. doi: 10.1172/JCI167952.
2
Diabetes and obesity treatment based on dual incretin receptor activation: 'twincretins'.基于双重肠促胰岛素受体激活的糖尿病和肥胖治疗：“双激素”。
Diabetes Obes Metab. 2016 Sep;18(9):847-54. doi: 10.1111/dom.12685. Epub 2016 Jun 7.
3
Endogenous glucagon-like peptide (GLP)-1 as alternative for GLP-1 receptor agonists: Could this work and how?内源性胰高血糖素样肽(GLP)-1 作为 GLP-1 受体激动剂的替代品：这是否可行，以及如何实现？
Diabetes Metab Res Rev. 2023 Nov;39(8):e3699. doi: 10.1002/dmrr.3699. Epub 2023 Jul 24.
4
Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity/Metabolic Syndrome, Prediabetes/Diabetes and Non-Alcoholic Fatty Liver Disease-Current Evidence.胰高血糖素样肽-1受体激动剂及双重葡萄糖依赖性促胰岛素多肽/胰高血糖素样肽-1受体激动剂在肥胖/代谢综合征、糖尿病前期/糖尿病及非酒精性脂肪性肝病治疗中的应用——当前证据
J Cardiovasc Pharmacol Ther. 2022 Jan-Dec;27:10742484221146371. doi: 10.1177/10742484221146371.
5
Harnessing glucagon-like peptide-1 receptor agonists for the pharmacological treatment of overweight and obesity.利用胰高血糖素样肽-1受体激动剂进行超重和肥胖的药物治疗。
Obes Rev. 2017 Jan;18(1):86-98. doi: 10.1111/obr.12465. Epub 2016 Sep 16.
6
Newer GLP-1 receptor agonists and obesity-diabetes.新型 GLP-1 受体激动剂与肥胖-糖尿病。
Peptides. 2018 Feb;100:61-67. doi: 10.1016/j.peptides.2017.12.009.
7
[From GLP1 receptor agonists to triple hormone receptor activation supplemented with glucagon receptor agonism.].[从胰高血糖素样肽-1受体激动剂到补充胰高血糖素受体激动作用的三重激素受体激活。]
Orv Hetil. 2023 Oct 22;164(42):1656-1664. doi: 10.1556/650.2023.32894.
8
Glucagon-like peptide-1 receptor agonists: the key to healthy weight loss maintenance?胰高血糖素样肽-1受体激动剂：维持健康体重减轻的关键？
Cardiovasc Res. 2021 Aug 29;117(10):e120-e122. doi: 10.1093/cvr/cvab249.
9
Gut hormone-based pharmacology: novel formulations and future possibilities for metabolic disease therapy.基于肠道激素的药物学：代谢性疾病治疗的新型制剂和未来可能。
Diabetologia. 2023 Oct;66(10):1796-1808. doi: 10.1007/s00125-023-05929-0. Epub 2023 May 20.
10
Effects of gastric inhibitory polypeptide, glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists on Bone Cell Metabolism.胃抑制肽、胰高血糖素样肽-1 和胰高血糖素样肽-1 受体激动剂对骨细胞代谢的影响。
Basic Clin Pharmacol Toxicol. 2018 Jan;122(1):25-37. doi: 10.1111/bcpt.12850. Epub 2017 Aug 11.

引用本文的文献

1
Effects of Glucagon-Like Peptide-1 receptor agonists on bone health in people living with obesity.胰高血糖素样肽-1受体激动剂对肥胖人群骨骼健康的影响。
Osteoporos Int. 2025 Sep 8. doi: 10.1007/s00198-025-07664-1.
2
A novel human specific lncRNA MEK6-AS1 regulates adipogenesis and fatty acid biosynthesis by stabilizing MEK6 mRNA.一种新型的人类特异性长链非编码RNA MEK6-AS1通过稳定MEK6 mRNA来调节脂肪生成和脂肪酸生物合成。
J Biomed Sci. 2025 Jan 8;32(1):6. doi: 10.1186/s12929-024-01098-3.
3
Role of incretins and glucagon receptor agonists in metabolic dysfunction-associated steatotic liver disease: Opportunities and challenges.

本文引用的文献

1
Tirzepatide Once Weekly for the Treatment of Obesity.司美格鲁肽每周一次治疗肥胖症。
N Engl J Med. 2022 Jul 21;387(3):205-216. doi: 10.1056/NEJMoa2206038. Epub 2022 Jun 4.
2
GIPR Agonism Inhibits PYY-Induced Nausea-Like Behavior.GIPR 激动剂抑制 PYY 诱导的恶心样行为。
Diabetes. 2022 Jul 1;71(7):1410-1423. doi: 10.2337/db21-0848.
3
Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension.停用司美格鲁肽后的体重反弹和心脏代谢影响：STEP 1 试验延伸。
肠促胰岛素和胰高血糖素受体激动剂在代谢功能障碍相关脂肪性肝病中的作用：机遇与挑战
World J Hepatol. 2024 May 27;16(5):731-750. doi: 10.4254/wjh.v16.i5.731.
4
Dual and Triple Incretin-Based Co-agonists: Novel Therapeutics for Obesity and Diabetes.基于双重和三重肠促胰岛素的共激动剂：肥胖症和糖尿病的新型疗法。
Diabetes Ther. 2024 May;15(5):1069-1084. doi: 10.1007/s13300-024-01566-x. Epub 2024 Apr 4.
5
The Cardiovascular Effect of Tirzepatide: A Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide Dual Agonist.替尔泊肽的心血管效应：一种胰高血糖素样肽-1和葡萄糖依赖性促胰岛素多肽双重激动剂
J Lipid Atheroscler. 2023 Sep;12(3):213-222. doi: 10.12997/jla.2023.12.3.213. Epub 2023 Jul 19.
6
The future of incretins in the treatment of obesity and non-alcoholic fatty liver disease.肠促胰岛素在肥胖和非酒精性脂肪性肝病治疗中的未来。
Diabetologia. 2023 Oct;66(10):1846-1858. doi: 10.1007/s00125-023-05966-9. Epub 2023 Jul 27.
Diabetes Obes Metab. 2022 Aug;24(8):1553-1564. doi: 10.1111/dom.14725. Epub 2022 May 19.
4
Anorectic and aversive effects of GLP-1 receptor agonism are mediated by brainstem cholecystokinin neurons, and modulated by GIP receptor activation.GLP-1 受体激动剂的厌食和厌恶作用是由脑干胆囊收缩素神经元介导的，并受 GIP 受体激活的调节。
Mol Metab. 2022 Jan;55:101407. doi: 10.1016/j.molmet.2021.101407. Epub 2021 Nov 26.
5
Anti-obesity drug discovery: advances and challenges.抗肥胖药物的发现：进展与挑战。
Nat Rev Drug Discov. 2022 Mar;21(3):201-223. doi: 10.1038/s41573-021-00337-8. Epub 2021 Nov 23.
6
Danuglipron (PF-06882961) in type 2 diabetes: a randomized, placebo-controlled, multiple ascending-dose phase 1 trial.在 2 型糖尿病中的丹格列净（PF-06882961）：一项随机、安慰剂对照、多次递增剂量的 1 期试验。
Nat Med. 2021 Jun;27(6):1079-1087. doi: 10.1038/s41591-021-01391-w. Epub 2021 Jun 14.
7
Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study.考达曲肽对超重或肥胖合并 2 型糖尿病成人代谢和肝脏参数的影响：一项 54 周随机 2b 期研究。
Diabetes Care. 2021 Jun;44(6):1433-1442. doi: 10.2337/dc20-2151. Epub 2021 May 20.
8
GIP mediates the incretin effect and glucose tolerance by dual actions on α cells and β cells.GIP 通过对 α 细胞和 β 细胞的双重作用来介导肠促胰岛素效应和葡萄糖耐量。
Sci Adv. 2021 Mar 12;7(11). doi: 10.1126/sciadv.abf1948. Print 2021 Mar.
9
Once-Weekly Semaglutide in Adults with Overweight or Obesity.每周一次司美格鲁肽在超重或肥胖成人中的应用。
N Engl J Med. 2021 Mar 18;384(11):989-1002. doi: 10.1056/NEJMoa2032183. Epub 2021 Feb 10.
10
Spatiotemporal GLP-1 and GIP receptor signaling and trafficking/recycling dynamics induced by selected receptor mono- and dual-agonists.受选定的受体单激动剂和双重激动剂诱导的 GLP-1 和 GIP 受体的时空信号转导和转运/再循环动力学。
Mol Metab. 2021 Jul;49:101181. doi: 10.1016/j.molmet.2021.101181. Epub 2021 Feb 6.